These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine. Halperin EC; Brizel DM; Honore G; Sontag MR; Griffith OW; Bigner DD; Friedman HS Int J Radiat Oncol Biol Phys; 1992; 24(1):103-9. PubMed ID: 1512145 [TBL] [Abstract][Full Text] [Related]
3. Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. Friedman HS; Colvin OM; Griffith OW; Lippitz B; Elion GB; Schold SC; Hilton J; Bigner DD J Natl Cancer Inst; 1989 Apr; 81(7):524-7. PubMed ID: 2921776 [TBL] [Abstract][Full Text] [Related]
4. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437 [TBL] [Abstract][Full Text] [Related]
6. The effect of glutathione (GSH) depletion in vivo by buthionine sulfoximine (BSO) on the radiosensitization of SR 2508. Kramer RA; Soble M; Howes AE; Montoya VP Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1325-9. PubMed ID: 2523885 [TBL] [Abstract][Full Text] [Related]
7. Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas. Fekete I; Griffith OW; Schlageter KE; Bigner DD; Friedman HS; Groothuis DR Cancer Res; 1990 Feb; 50(4):1251-6. PubMed ID: 2297773 [TBL] [Abstract][Full Text] [Related]
8. Effect of L-buthionine sulfoximine on the radiation response of human renal carcinoma cell lines. Leung SW; Mitchell JB; al-Nabulsi I; Friedman N; Newsome J; Belldegrun A; Kasid U Cancer; 1993 Apr; 71(7):2276-85. PubMed ID: 8095848 [TBL] [Abstract][Full Text] [Related]
9. Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508. Yu NY; Brown JM Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1265-9. PubMed ID: 6236185 [TBL] [Abstract][Full Text] [Related]
10. The toxic effects, GSH depletion and radiosensitivity by BSO on retinoblastoma. Yi X; Ding L; Jin Y; Ni C; Wang W Int J Radiat Oncol Biol Phys; 1994 May; 29(2):393-6. PubMed ID: 8195039 [TBL] [Abstract][Full Text] [Related]
11. Influence of buthionine sulfoximine and misonidazole on glutathione level and radiosensitivity of human tumor xenografts. Guichard M; Lespinasse F; Malaise EP Radiat Res; 1986 Jan; 105(1):115-25. PubMed ID: 3945723 [TBL] [Abstract][Full Text] [Related]
12. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434 [TBL] [Abstract][Full Text] [Related]
13. Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine. Skapek SX; VanDellen AF; McMahon DP; Postels DG; Griffith OW; Bigner DD; Friedman HS Cancer Chemother Pharmacol; 1991; 28(1):15-21. PubMed ID: 2040029 [TBL] [Abstract][Full Text] [Related]
14. Enhancement of EMT6/SF tumor cell killing by mitomycin C and cyclophosphamide following in vivo administration of buthionine sulfoximine. Ono K; Shrieve DC Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1175-8. PubMed ID: 3091546 [TBL] [Abstract][Full Text] [Related]
15. Radiosensitizing effect of misonidazole in combination with an inhibitor of glutathione synthesis in murine tumors. Ono K; Komuro C; Nishidai T; Shibamoto Y; Tsutsui K; Takahashi M; Abe M Int J Radiat Oncol Biol Phys; 1986 Sep; 12(9):1661-6. PubMed ID: 3759592 [TBL] [Abstract][Full Text] [Related]
16. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155 [TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine. Malaker K; Hurwitz SJ; Bump EA; Griffith OW; Lai LL; Riese N; Coleman CN Int J Radiat Oncol Biol Phys; 1994 May; 29(2):407-12. PubMed ID: 7910818 [TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977 [TBL] [Abstract][Full Text] [Related]
19. Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro. Shrieve DC; Denekamp J; Minchinton AI Radiat Res; 1985 Jun; 102(3):283-94. PubMed ID: 4070545 [TBL] [Abstract][Full Text] [Related]
20. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells. Dethlefsen LA; Lehman CM; Biaglow JE; Peck VM Radiat Res; 1988 May; 114(2):215-24. PubMed ID: 3375425 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]